{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:05:35Z","timestamp":1790809535190,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Purpose\u2014<\/jats:title>\n                    <jats:p>Poststroke cognitive impairment is a debilitating consequence of stroke. The aim of this study was to assess whether Actovegin confers cognitive benefit in patients who have had an ischemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\u2014<\/jats:title>\n                    <jats:p>This was a 12-month, parallel-group, randomized, multicenter, double-blind, placebo-controlled study. Eligible patients were \u226560 years of age with a Montreal Cognitive Assessment test score of \u226425 points. Patients were randomized into 2 groups within 1 week of acute supratentorial ischemic stroke in a 1:1 ratio: Actovegin (a deproteinized hemoderivative of calf blood, 2000 mg\/d for \u226420 intravenous infusions followed by 1200 mg\/d orally) or placebo for 6 months. Patients were treated in accordance with standard clinical practice for a further 6 months. The primary end point was the change from baseline in Alzheimer\u2019s Disease Assessment Scale, cognitive subscale, extended version at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\u2014<\/jats:title>\n                    <jats:p>\n                      Two-hundred forty-eight patients were randomized to Actovegin and 255 patients to placebo. At month 6, the least squares mean change from baseline in Alzheimer\u2019s Disease Assessment Scale, cognitive subscale, extended version was \u22126.8 for Actovegin and \u22124.6 for placebo; the estimated treatment difference was \u22122.3 (95% confidence interval, \u22123.9, \u22120.7;\n                      <jats:italic>P<\/jats:italic>\n                      =0.005). Recurrent ischemic stroke was the most frequently reported serious adverse event, with a nonsignificantly higher number for Actovegin versus placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\u2014<\/jats:title>\n                    <jats:p>Actovegin had a beneficial effect on cognitive outcomes in patients with poststroke cognitive impairment. The safety experience was consistent with the known safety and tolerability profile of the drug. These results warrant confirmation in additional robustly designed studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      . Unique identifier: NCT01582854.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/strokeaha.116.014321","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T21:10:47Z","timestamp":1492809047000},"page":"1262-1270","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":79,"title":["ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin)"],"prefix":"10.1161","volume":"48","author":[{"given":"Alla","family":"Guekht","sequence":"first","affiliation":[{"name":"From the Department of Neurology, Neurosurgery and Genetics, Russian National Research Medical University Moscow and Clinical Center for Neuropsychiatry, Russia (A.G.); Sahlgrenska Academy, University of Gothenburg, Sweden (I.S.); Takeda Development Centre Europe, London, United Kingdom (S.E.); Department of Neurology, First Moscow State Medical University, Russia (V.Z.); and Department of Neurology, Tel Aviv University, Israel (A.D.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmar","family":"Skoog","sequence":"additional","affiliation":[{"name":"From the Department of Neurology, Neurosurgery and Genetics, Russian National Research Medical University Moscow and Clinical Center for Neuropsychiatry, Russia (A.G.); Sahlgrenska Academy, University of Gothenburg, Sweden (I.S.); Takeda Development Centre Europe, London, United Kingdom (S.E.); Department of Neurology, First Moscow State Medical University, Russia (V.Z.); and Department of Neurology, Tel Aviv University, Israel (A.D.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Edmundson","sequence":"additional","affiliation":[{"name":"From the Department of Neurology, Neurosurgery and Genetics, Russian National Research Medical University Moscow and Clinical Center for Neuropsychiatry, Russia (A.G.); Sahlgrenska Academy, University of Gothenburg, Sweden (I.S.); Takeda Development Centre Europe, London, United Kingdom (S.E.); Department of Neurology, First Moscow State Medical University, Russia (V.Z.); and Department of Neurology, Tel Aviv University, Israel (A.D.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Zakharov","sequence":"additional","affiliation":[{"name":"From the Department of Neurology, Neurosurgery and Genetics, Russian National Research Medical University Moscow and Clinical Center for Neuropsychiatry, Russia (A.G.); Sahlgrenska Academy, University of Gothenburg, Sweden (I.S.); Takeda Development Centre Europe, London, United Kingdom (S.E.); Department of Neurology, First Moscow State Medical University, Russia (V.Z.); and Department of Neurology, Tel Aviv University, Israel (A.D.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos D.","family":"Korczyn","sequence":"additional","affiliation":[{"name":"From the Department of Neurology, Neurosurgery and Genetics, Russian National Research Medical University Moscow and Clinical Center for Neuropsychiatry, Russia (A.G.); Sahlgrenska Academy, University of Gothenburg, Sweden (I.S.); Takeda Development Centre Europe, London, United Kingdom (S.E.); Department of Neurology, First Moscow State Medical University, Russia (V.Z.); and Department of Neurology, Tel Aviv University, Israel (A.D.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61953-4"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61689-4"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.005143"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70236-4"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12626"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-97"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-015-0367-0"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.01.012"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.07.069"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041460119"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-011-8157-7"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4943(89)90038-1"},{"key":"e_1_3_4_15_2","first-page":"451","article-title":"[The electroencephalogram of the rat in oxygen deficiency as an indicator of drug effects on cerebral metabolism].","volume":"22","author":"Kr\u00fcger G","year":"1972","unstructured":"Kr\u00fcger G, Quadbeck G. [The electroencephalogram of the rat in oxygen deficiency as an indicator of drug effects on cerebral metabolism]. Arzneimittelforschung. 1972;22:451\u2013456.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_4_16_2","first-page":"681","article-title":"[Pharmacological effect of Solcoseryl on the metabolism of the brain. Animal experiments and clinical research].","volume":"125","author":"Lanner G","year":"1975","unstructured":"Lanner G, Argyropoulos. [Pharmacological effect of Solcoseryl on the metabolism of the brain. Animal experiments and clinical research]. Wien Med Wochenschr. 1975;125:681\u2013685.","journal-title":"Wien Med Wochenschr"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12297"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(90)90007-W"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000119042"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11055-008-9051-0"},{"issue":"9","key":"e_1_3_4_21_2","first-page":"13","article-title":"[Efficacy and safety of the combined therapy with citicholine and actovegin in the acute period of ischemic stroke].","volume":"110","author":"Shamalov NA","year":"2010","unstructured":"Shamalov NA, Stakhovskaia LV, Shetova IM, Efremova NM, Anisimov KV. [Efficacy and safety of the combined therapy with citicholine and actovegin in the acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(9 pt 2):13\u201317.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/17461391.2015.1130750"},{"key":"e_1_3_4_23_2","unstructured":"Actovegin 80 mg Injection Solution - Summary of Product Characteristics (SPC). Http:\/\/www.Pharmazie.Com\/graphic\/a\/17\/2-00017.Pdf. Accessed November 15 2016."},{"key":"e_1_3_4_24_2","unstructured":"Ramipril 1.25 mg Capsules - Summary of Product Characteristics (SPC). Https:\/\/www.Medicines.Org.Uk\/emc\/medicine\/24132. Accessed November 15 2016."},{"key":"e_1_3_4_25_2","unstructured":"Memantine Accord 20 mg Film-Coated Tablets - Summary of Product Characteristics (SPC). Https:\/\/www.Medicines.Org.Uk\/emc\/medicine\/28669. Accessed November 15 2016."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000357122"},{"key":"e_1_3_4_27_2","volume-title":"Guideline on Missing Data in Confirmatory Clinical Trials","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/09\/WC500096793.pdf. Accessed April 11, 2017."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2010.08.052"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.204008"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-012-9166-3"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00009"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.496"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-1930"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.633586"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2011.121"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04807.x"},{"key":"e_1_3_4_37_2","volume-title":"Guideline on Medicinal Products for the Treatment of Alzheimer\u2019s Disease and Other Dementias","author":"European Medicines Agency","unstructured":"European Medicines Agency. Guideline on Medicinal Products for the Treatment of Alzheimer\u2019s Disease and Other Dementias. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003562.pdf. Accessed April 11, 2017."},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0b013e3182299496"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000352051"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.2.333"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-011-0865-y"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.116.014321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:00:21Z","timestamp":1715598021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.116.014321"}},"subtitle":["A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1161\/STROKEAHA.116.014321"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.116.014321","relation":{"has-review":[{"id-type":"doi","id":"10.14322\/PUBLONS.R2328587","asserted-by":"object"},{"id-type":"doi","id":"10.14322\/PUBLONS.R2306813","asserted-by":"object"}]},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2016-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}